Annals of the Rheumatic Diseases

Journal

Publication Venue For

  • Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. 2020
  • SARS CoV-2 infection among patients using immunomodulatory therapies. 2020
  • Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry.  79:859-866. 2020
  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.  79:S685-S699. 2020
  • Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.  79:573. 2020
  • Hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data.  79:529-535. 2020
  • Allopurinol versus febuxostat hypersensitivity reactions in the US elderly: Differences in study outcomes and populations. Response to: 'Correspondence to "hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data' by Ma et al 2020
  • Hypersensitivity reactions with allopurinol versus febuxostat in the US elderly. Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data'' by Hsu et al 2020
  • Response to: Â &tild; Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al 2020
  • Response to: € Cutaneous adverse events with febuxostat after previous reactions to allopurinol: Comment on the artcile by Singh and Clevland' by Quills et al 2020
  • Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.  78:1592-1600. 2019
  • Response to: 'Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg.  78. 2019
  • Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.  78:1055-1061. 2019
  • Gout is associated with increased healthcare utilization after knee arthroplasty.  78:1146-1148. 2019
  • Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.  78:1010-1012. 2019
  • Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.  78:355-364. 2019
  • Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.  78:355-364. 2019
  • Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada.  78. 2019
  • Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: Reality or dream?.  78:153-154. 2019
  • Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis 2019
  • Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.  78:1357-1362. 2019
  • Emergent high fatality lung disease in systemic juvenile arthritis.  78:1722-1731. 2019
  • Neuropsychiatric events in systemic lupus erythematosus: A longitudinal analysis of outcomes in an international inception cohort using a multistate model approach 2019
  • Remission or low disease activity as a target in systemic lupus erythematosus.  78. 2019
  • First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).  77:1549-1557. 2018
  • Response to: 'Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song.  77:e74. 2018
  • Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults.  77:1243-1245. 2018
  • Response to: 'A response to singh. “Lesinurad combination therapy with allopurinol in gout: Do CLEAR studies make the treatment of gout clearer?”' by valiyil and schechter.  77. 2018
  • Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.  77:1012-1016. 2018
  • Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.  77:644-649. 2018
  • EULAR gout treatment guidelines by Richette et al.: Uric acid and neurocognition.  77. 2018
  • Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study.  77:386-392. 2018
  • Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking.  77:317-318. 2018
  • 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.  76:1955-1964. 2017
  • Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).  76:2071-2074. 2017
  • Weight loss for overweight and obese individuals with gout: A systematic review of longitudinal studies.  76:1870-1882. 2017
  • Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: An analysis of Medicare claims data.  76:1669-1678. 2017
  • Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990-2013: Findings from the Global Burden of Disease Study 2013.  76:1365-1373. 2017
  • Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials.  76:1253-1262. 2017
  • Lesinurad combination therapy with allopurinol in gout: Do CLEAR studies make the treatment of gout clearer?.  76:779-781. 2017
  • Chasing crystals out of the body: Will treat to serum urate target for gout help us get there?.  76:629-631. 2017
  • Treat-To-Target (T2T) recommendations for gout.  76:632-638. 2017
  • Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.  76:543-546. 2017
  • Allopurinol and the risk of atrial fibrillation in the elderly: A study using medicare data.  76:72-78. 2017
  • Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.  76:133-139. 2017
  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.  76:960-977. 2017
  • Renal dosing of allopurinol results in suboptimal gout care.  76. 2017
  • Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.  75:2007-2013. 2016
  • Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.  75:1813-1818. 2016
  • Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.  75:1757-1762. 2016
  • Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.  75:1843-1847. 2016
  • Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: To worry or not to worry?.  75:1265-1267. 2016
  • Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme.  75:831-841. 2016
  • 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative.  75:481-489. 2016
  • Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health Administration.  75:341-347. 2016
  • Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.  75:242-252. 2016
  • Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: Consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.  74:2107-2116. 2015
  • 2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative.  74:1789-1798. 2015
  • A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk.  74:1875-1881. 2015
  • Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.  74:1706-1713. 2015
  • Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort.  74:1530-1536. 2015
  • Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.  74:963-969. 2015
  • Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: Persistent benefits. Data from the Corrona registry.  74:1150-1155. 2015
  • Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.  74:1065-1071. 2015
  • The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort.  74:1019-1023. 2015
  • Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: Trait or state?.  74:682-688. 2015
  • When gout goes to the heart: Does gout equal a cardiovascular disease risk factor?.  74:631-634. 2015
  • The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.  74:430-436. 2015
  • Racial disparities in knee and hip total joint arthroplasty: An 18-year analysis of national medicare data.  73:2107-2115. 2014
  • Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) study.  73:1942-1948. 2014
  • A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab.  73:1429-1430. 2014
  • Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis.  73:785-786. 2014
  • The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.  73:1301-1308. 2014
  • Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.  72:1813-1818. 2013
  • Clinical associations of the metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort.  72:1308-1314. 2013
  • Serum urate association with hypertension in young adults: Analysis from the Coronary Artery Risk Development in Young Adults cohort.  72:1321-1327. 2013
  • Co-localisation of non-cartilaginous articular pathology increases risk of cartilage loss in the tibiofemoral joint - The MOST study.  72:942-948. 2013
  • Fine mapping of Xq28: Both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups.  72:437-444. 2013
  • Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2).  72:204-210. 2013
  • The role of varus and valgus alignment in the initial development of knee cartilage damage by MRI: The MOST study.  72:235-240. 2013
  • Mycobacterial diseases and antitumour necrosis factor therapy in USA.  72:37-42. 2013
  • Breaking the law of valgus: The surprising and unexplained prevalence of medial patellofemoral cartilage damage.  71:1827-1832. 2012
  • Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries.  71:1809-1814. 2012
  • Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.  71:1502-1509. 2012
  • A role for PACE4 in osteoarthritis pain: Evidence from human genetic association and null mutant phenotype.  71:1042-1048. 2012
  • Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study.  71:924-928. 2012
  • Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus.  71:694-699. 2012
  • Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G.  71:777-784. 2012
  • IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.  71:463-468. 2012
  • Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE study.  71:198-205. 2012
  • Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trial.  71:206-212. 2012
  • Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty.  70:2082-2088. 2011
  • Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.  70:1726-1732. 2011
  • Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus.  70:1752-1757. 2011
  • Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: The MOST study.  70:1804-1809. 2011
  • Risk factors for medial meniscal pathology on knee MRI in older US adults: A multicentre prospective cohort study.  70:1733-1739. 2011
  • The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.  70:1401-1406. 2011
  • Validation of pain and patient global scales in chronic gout: Data from two randomised controlled trials.  70:1277-1281. 2011
  • SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.  70:961-967. 2011
  • Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: The MOST study.  70:805-811. 2011
  • High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.  70:785-791. 2011
  • Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.  70:576-582. 2011
  • US patients of hispanic and African ancestry develop lupus nephritis early in the disease course: Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV).  70:393-394. 2011
  • An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA.  70:54-59. 2011
  • Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity.  69:1920-1925. 2010
  • Serum urate and its relationship with alcoholic beverage intake in men and women: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.  69:1965-1970. 2010
  • Varus and valgus alignment and incident and progressive knee osteoarthritis.  69:1940-1945. 2010
  • Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.  69:1612-1617. 2010
  • From bone biology to clinical outcome: State of the art and future perspectives.  69:1415-1419. 2010
  • ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry.  69:1329-1332. 2010
  • Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.  69:1015-1021. 2010
  • Subchondral bone attrition may be a reflection of compartment-specific mechanical load: The MOST Study.  69:841-844. 2010
  • Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans.  69:625-626. 2010
  • The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases.  69:696-699. 2010
  • Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.  69:529-535. 2010
  • Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.  69:43-47. 2010
  • High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: The MOST study.  69:163-168. 2010
  • Meniscal pathology on MRI increases the risk for both incident and enlarging subchondral bone marrow lesions of the knee: The MOST study.  69:1796-1802. 2010
  • Relation of synovitis to knee pain using contrast-enhanced MRIs.  69:1779-1783. 2010
  • Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases.  68:1800-1804. 2009
  • Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: The MOST Study. A longitudinal multicentre study of knee osteoarthritis.  68:1461-1465. 2009
  • Opportunities for improving medication use and monitoring in gout.  68:1265-1270. 2009
  • Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.  67:1724-1731. 2008
  • Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis.  67:1529-1534. 2008
  • Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?.  67:1358-1359. 2008
  • Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells.  67:1488-1492. 2008
  • Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.  67:1310-1316. 2008
  • Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII).  67:1170-1173. 2008
  • A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.  67:888-891. 2008
  • Seizures in patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic cohort (LUMINA LIV).  67:829-834. 2008
  • Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: Disease expression and outcome in acute onset lupus.  67:500-504. 2008
  • The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study.  67:74-79. 2008
  • EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.  66:1560-1567. 2007
  • Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L).  66:1168-1172. 2007
  • African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: Results from LUMINA, a multiethnic cohort (LUMINAXLV).  66:618-622. 2007
  • Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): Factors predictive of self-reported work disability.  66:12-17. 2007
  • Sex differences in gout epidemiology: Evaluation and treatment.  65:1368-1372. 2006
  • Racial or ethnic differences in allele frequencies of sinqle-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.  65:1213-1218. 2006
  • Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women.  65:1163-1167. 2006
  • Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.  65:1168-1174. 2006
  • Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: Results of a nested matched case-control study.  65:785-790. 2006
  • Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data.  65:285-293. 2006
  • Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren's syndrome.  64:1050-1055. 2005
  • Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999.  64:267-272. 2005
  • Immunohistochemistry of normal synovium [2] (multiple letters).  63:1532-1533. 2004
  • Immunohistochemistry of normal human knee synovium: A quantitative study.  63:785-790. 2004
  • Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres.  63:245-251. 2004
  • Glucocorticoids in the treatment of early and late RA.  62:1033-1037. 2003
  • The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome.  62:168-171. 2003
  • Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: Results from the Iowa Women's Health Study.  61:994-999. 2002
  • Cigarette smoking and rheumatoid arthritis severity.  56:463-469. 1997
  • Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout..  55:489-490. 1996
  • Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients.  54:708-712. 1995
  • Folate supplementation and methotrexate [3].  52:315-316. 1993
  • Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction?.  52. 1993
  • Controlled trial of methotrexate versus 10-deazaaminopterin in the treatment of rheumatoid arthritis.  51:600-603. 1992
  • False positive results for antibody to HIV in two men with systemic lupus erythematosus.  51:1071-1073. 1992
  • Local immune responses in certain extra-articular manifestations of rheumatoid arthritis.  51:698-701. 1992
  • 5-Fluorouracil in the treatment of scleroderma: A randomised, double blind, placebo controlled international collaborative study.  49:926-928. 1990
  • Osteoarthritis: Definitions and criteria.  49:201. 1990
  • Auricular chondritis and diffuse proliferative glomerulonephritis in primary Sjögren's syndrome.  48:683-685. 1989
  • Pulmonary hypertension in primary Sjogren's syndrome.  47:251-253. 1988
  • Sarcoidosis presenting as antinuclear antibody positive glomerulonephritis.  47:337-339. 1988
  • Brucellar arthritis: A study of 39 Peruvian families.  46:506-509. 1987
  • A new promising treatment in systemic sclerosis: 5-fluorouracil.  46:763-767. 1987
  • Rheumatic manifestations of brucellosis..  45:526. 1986
  • Tissue typing in brucellosis..  45:351. 1986
  • Multiple microcrystal deposition disease in a patient with systemic lupus erythematosus.  43:498-502. 1984
  • International Standard Serial Number (issn)

  • 0003-4967
  • Electronic International Standard Serial Number (eissn)

  • 1468-2060